Condition
Fat loss
20 compounds were checked against fat loss. 8 earned a graded row; the rest are named below.
Last updated
Recorded under Weight, alongside 4 other indications.
Compounds with a graded row
Ordered by rung, strongest first. The rung rates the study design; the chip beside it says what the study measured. Both are needed.
-
L-Carnitine
human RCT Direct outcome Not approved for this condition
- Who was studied
- adults across 37 randomised controlled trials, 2292 participants pooled; effect reported as confined to adults with overweight or obesity; trial durations vary
A meta-analysis of 37 randomised controlled trials found pooled reductions of 1.21 kg in body weight, 0.24 kg/m2 in BMI and 2.08 kg in fat mass, with no significant change in body fat percent or waist circumference. Fat mass was measured, so this is not scale weight alone, but the unchanged body fat percent means the data do not establish a shift in composition. Restricting to high-quality trials confirmed only the body-weight effect, and the reported benefit was in overweight and obese participants.
Source PubMed 1 primary source read for this row
-
Retatrutide
human RCT Direct outcome In registered trials
- Who was studied
- adults with type 2 diabetes, HbA1c 7.0-10.5%, BMI 25-50; body-composition substudy n=189 randomised, 103 with both baseline and week-36 DXA scans, 36 weeks
A prespecified DXA substudy of a phase 2 randomised placebo-controlled trial measured percent change in total body fat mass at 36 weeks: reductions of 15.2% (4 mg pooled), 26.1% (8 mg pooled) and 23.2% (12 mg) versus 4.5% with placebo. The population was people with type 2 diabetes, not healthy adults seeking body-composition change. The separate phase 2 obesity trial (n=338, 48 weeks, BMI 30+ or 27+ with a weight-related condition) reported scale weight only, so fat loss as distinct from weight loss rests on the diabetes substudy.
Source PubMed 2 primary sources read for this row
-
Tesamorelin
human RCT Direct outcome Not approved for this condition
- Who was studied
- HIV-infected adults with lipodystrophy and excess abdominal fat; study 1 n=412 (273 drug / 137 placebo), study 2 n=404 (270 / 126); 26-week main phase
Two randomised, double-blind, placebo-controlled trials measured visceral adipose tissue by CT at 26 weeks: mean reductions of 27 cm2 and 21 cm2 versus a 4 cm2 increase and no change on placebo. The FDA approval (EGRIFTA SV) is specifically for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, a disease population; the label addresses no non-HIV population, and no trial in healthy adults seeking body-composition change is on file.
Source DailyMed — the FDA label 1 primary source read for this row
-
IGF-1
human case series Surrogate marker Not approved for this condition
- Who was studied
- obese insulin-resistant patients with type II diabetes, n=12 recruited, 6 completing 6 weeks; body composition by dual energy x-ray absorptiometry
The only fat-mass measurement on file for IGF-I is incidental to a glucose study: a 2.1% loss in body fat by DXA over six weeks, with no change in total bodyweight. It was not a stated endpoint, there was no control group, and the population was diabetic rather than someone seeking fat loss. No trial has set out to test IGF-I for fat loss, so what exists is one uncontrolled six-week observation in twelve people, half of whom stopped early. Rung set by review: the same twelve uncontrolled patients — one study has one rung.
Source PubMed 1 primary source read for this row
-
5-Amino-1MQ
animal in vivo Surrogate marker Not approved for this condition
- Who was studied
- diet-induced obese mice, systemic administration; no human study located
A potent NNMT inhibitor reduced body weight and white adipose tissue mass in diet-induced obese mice without changing food intake. Adipose mass was measured, not scale weight alone, but the measurement was in mice. No human study of 5-amino-1MQ measuring body weight or body composition is on file.
Source PubMed 1 primary source read for this row
-
AOD-9604
animal in vivo Surrogate marker Not approved for this condition
- Who was studied
- obese mice and beta-3 adrenergic receptor knock-out mice, 14 days intraperitoneal administration; no readable human study
Chronic intraperitoneal AOD9604 reduced body weight and body fat in obese mice over 14 days; the effect on body weight and lipolysis was absent in beta-3 adrenergic receptor knock-out mice. Human trials of AOD-9604 are described in review articles only: no primary report of any AOD-9604 human trial could be reached, so no human row is graded here and the review accounts are not cited.
Source Oxford Academic 1 primary source read for this row
-
HGH Frag 176-191
animal in vivo Surrogate marker Not approved for this condition
- Who was studied
- obese Zucker rats given 500 micrograms/kg bodyweight orally each day for 19 days; group sizes not stated in the abstract
Bodyweight gain over 19 days was 15.8 g against 35.6 g in controls, and lipolytic activity in adipose tissue rose. Euglycaemic clamp showed no adverse effect on insulin sensitivity, in contrast to intact growth hormone. What is measured is weight gain prevented and tissue lipolysis, not fat mass on a scan, and the animal is a genetically obese rat. No human measurement of fat loss with this compound exists. Rung set from the study's own design wording, "rats".
Source PubMed 1 primary source read for this row
-
MOTS-c
animal in vivo Surrogate marker Not approved for this condition
- Who was studied
- mice, including aged and high-fat-diet-fed animals; no human study located
MOTS-c treatment prevented diet-induced obesity and age-dependent and diet-induced insulin resistance in mice, with skeletal muscle identified as the target tissue and AMPK activation as the mechanism. No human study of MOTS-c measuring body weight or body composition is on file.
Source PubMed 1 primary source read for this row
Recorded absences
10 compounds are listed here without a rung. Each row exists to mark a distinction a reader would otherwise draw wrongly, and each says what is missing rather than leaving the compound off the page.
-
CJC-1295 no-DAC
No rung — nothing on file to grade Not approved for this condition
No graded evidence exists on this record. Every citation attached to CJC-1295 no-DAC carries a null evidence rung, and the set consists of narrative reviews, an analytical-chemistry identification of the compound in an unknown pharmaceutical preparation, and a netnography of self-reported use. No study measuring body weight or body composition after CJC-1295 no-DAC administration, in humans or animals, is on file. The row is recorded because the compound is widely sold and stacked for this purpose.
-
CRH (Corticotropin-Releasing Hormone)
No rung — nothing on file to grade Not approved for this condition
Same as obesity. Nothing administered, nothing measured.
-
Enfuvirtide
No rung — nothing on file to grade Not approved for this condition
No trial has used enfuvirtide for fat loss. The only fat measurements on file come from the antiretroviral safety substudy above, where fat increased slightly.
-
GHRH (Growth Hormone-Releasing Hormone)
No rung — nothing on file to grade Not approved for this condition
No trial has used native GHRH against this condition; nothing retrieved measured fat mass after native GHRH.
-
GHRP-1
No rung — nothing on file to grade Not approved for this condition
No trial has used this compound against this condition; no study on file measured body fat after GHRP-1.
-
GHRP-2
No rung — nothing on file to grade Not approved for this condition
No trial has used this compound against this condition. Nothing retrieved measured fat mass after GHRP-2; the human studies on file measured growth hormone release and food intake over a single session.
-
Hexarelin
No rung — nothing on file to grade Not approved for this condition
No trial has used this compound against this condition; nothing retrieved measured body fat.
-
Setmelanotide
No rung — nothing on file to grade Not approved for this condition
Every trial on file measures bodyweight or BMI, not fat mass. No setmelanotide trial reports a body-composition scan, so there is no record of how much of the loss was fat.
-
Simonson Alpha 1
No rung — nothing on file to grade Not approved for this condition
No study exists to check. The name does not appear as a phrase anywhere in Europe PMC.
-
Vasopressin
No rung — nothing on file to grade Not approved for this condition
Same as obesity. No administered-peptide trial with a body composition outcome exists.
Checked, and nothing recorded
2 compounds were checked against fat loss and produced no gradeable row.
A compound is here because someone looked and the sources did not support a row — not because nobody looked. Under the rubric, uncertainty resolves to no row, and a row resting on a vendor page or a clinic blog is worse than no row at all.
What this page does not say
It reports what was measured, in whom, and how directly. It does not say what to take or at what dose, and a row here is a record of a study rather than a reason to use anything. Every rung links to the rubric that assigned it.